BioVentrix Announces Successful First-In-Man, Catheter-Based Endovascular Clinical Procedure
SAN RAMON, Calif., and VILNIUS, Lithuania, BioVentrix,
a pioneer of technologies and procedures for less-invasive treatment of heart
failure (HF), today announced the first-in-man use of its next generation
Revivent-TC™ System with an endovascular catheter-based approach from within
the left ventricle. The Less Invasive Ventricular Enhancement™ or the LIVE™
procedure, used to reshape and reduce the left ventricle (LV), now utilizes
deployment of its micro-anchor technology to exclude scar tissue from within
the vasculature and without opening the chest. The device was successfully
implanted in a 64-year-old female patient suffering from heart failure symptoms
as a result of a myocardial infarction. The procedure was performed by
Dr. med. Giedrius Davidavicius, Interventional Cardiologist, and Dr.
med. Gintaras Kalinauskas, Cardiothoracic
Surgeon, at Vilnius University Hospital inVilnius, Lithuania.
"We are very pleased with the results of the Revivent-TC™ endovascular delivery system and the immediate clinical benefit to the patient," said Dr. Davidavicius. "This new endovascular delivery system to exclude the scar from within the LV cavity reduces procedural risk, improves accuracy of anchor implant, and enables a more minimally invasive approach for patients suffering from this disease."
"For patients this fragile, they are often precluded from any meaningful intervention due to the risks and extended recovery," said Dr. Kalinauskas. "The new Revivent-TC™ endovascular approach has provided an opportunity for more patients who are suffering from ischemic cardiomyopathy to be treated; while the improved accuracy of anchor placement should lead to even better clinical outcomes for these patients," continued Dr. Kalinauskas.
"The success of this endovascular procedure shows our commitment to the development of the LIVE™ procedure to reach a fully percutaneous left ventricular volume reduction system for ischemic heart failure patients," said Dr. Lon Annest, Chief Medical Officer for BioVentrix, Inc. "This is a significant milestone for not only the company, but for all heart failure patients who suffer from ischemic cardiomyopathy," continued Dr. Annest.
BioVentrix has shown that the exclusion of scar tissue from the LV cavity in patients suffering from ischemic cardiomyopathy heart failure results in substantial improvements in Quality of Life. Additionally, previous studies reported in the surgical literature have shown that a significant LV volume reduction conveys a survival benefit for treated patients2.
Source: BioVentrix, Inc.
Comments